References
- Nelson HS, Weiss ST, Bleecker ER, et al. SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15–26. Erratum in: Chest 2006;129:1393
- Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034–7
- National Institutes of Health. National asthma education and prevention program (NAEPP). The NAEPP expert panel report 3 (EPR-3) summary report 2007: guidelines for the diagnosis and management of asthma. US Department of Health and Human Services; October 2007. NIH publication no. 08–5846
- US Food and Drug Administration (FDA). Drug safety communication: new safety requirements for long-acting inhaled asthma medications called long-acting beta-agonists (LABAs); 18 February, 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm [last accessed 15 Feb 2012]
- US Food and Drug Administration (FDA). Drug safety communication: drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called long-acting beta-agonists (LABAs); 2 June, 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htm [last accessed 15 Feb 2012]
- US Food and Drug Administration (FDA). Approved risk evaluation and mitigation strategies (REMS). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm [last accessed 13 Nov 2012]
- McMahon AW, Levenson MS, McEvoy BW, et al. Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists. Pediatrics 2011;128:e1147–54
- Sears MR. The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility? Thorax 2012;68:195–8
- US Food and Drug Administration (FDA). Risk evaluation and mitigation strategy (REMS): NDA 21-077 ADVAIR DISKUS® (fluticasone propionate and salmeterol xinafoate) inhalation powder; December 2010. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM241712.pdf [last accessed 15 Feb 2012]
- US Food and Drug Administration (FDA). Risk evaluation and mitigation strategy (REMS): NDA 20-692 SEREVENT DISKUS® (salmeterol xinafoate) inhalation powder; December 2010. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM241712.pdf [last accessed 15 Feb 2012]
- Source Healthcare Analytics. GlaxoSmithKline custom asthma/COPD hierarchical regimen analysis tool; January 2005–December 2011
- Source Healthcare Analytics. GlaxoSmithKline asthma/COPD annual unique patient counts (UPCs). January 2005–December 2011
- National Prescription Audit™ (NPA), IMS Health. January 2005–December 2011
- National Disease and Therapeutic Index™ (NDTI). IMS Health, January 2005–December 2011
- Optum™ Impact™ National Managed Care Benchmark Database. (OptumInsight, Eden Prairie, MN, USA) 2012
- Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7
- DiSantostefano RL, Davis KJ. Prescription patterns in asthma patients initiating salmeterol in UK general practice: a retrospective cohort study using the General Practice Research Database (GPRD). Drug Saf. 2011;34:511–20
- Wasilevich EA, Clark SJ, Cohn LM, Dombkowski KJ. Long-acting β-agonist monotherapy among children and adults with asthma. Am J Manag Care 2011;17:e91–5
- Kaplan S, Zhou EH, Iyasu SI. Characterization of long-acting beta2-adrenergic agonists utilization in asthma patients. J Asthma 2012;49:1079–85
- Morales DR, Jackson C, Fielding S, Guthrie B. Long-acting β-agonist prescribing in people with asthma in primary care. Thorax 2013;68:192–4
- Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med 2005;99:1263–7
- Ye X, Gutierrez B, Zarotsky V, et al. Appropriate use of inhaled corticosteroid and long-acting beta (2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population. Curr Med Res Opin 2009;25:2251–8